CIK 0001281895 · Non-accelerated filer<br>Smaller reporting company
ROCKET PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RCKT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 646-440-9100
- Business address
- 350 FIFTH AVENUE, SUITE 7530, NEW YORK, NY, 10118
- Former names
- INOTEK PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $405,500
- in 5 filings
Net −$405,500. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-11 | Militello John See Remarks | Grant or award · Stock Option (Right to Buy) | +45,018 | 45,018 | ||
| 2026-02-11 | Wilson Martin General Counsel | Grant or award | +311,813 | 695,629 | ||
| 2026-02-11 | Wilson Martin General Counsel | Grant or award · Stock Option (Right to Buy) | +468,187 | 468,187 | ||
| 2026-02-11 | Rizvi Syed Ali-aamir Chief Medical Officer | Grant or award | +61,963 | 407,874 | ||
| 2026-02-11 | Rizvi Syed Ali-aamir Chief Medical Officer | Grant or award · Stock Option (right to buy) | +93,037 | 93,037 | ||
| 2026-02-11 | Stevens Christopher James Chief Operating Officer | Grant or award | +61,963 | 469,129 | ||
| 2026-02-11 | Stevens Christopher James Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +93,037 | 93,037 | ||
| 2026-02-11 | Chaudhuri Sarbani See Remarks | Grant or award | +125,924 | 285,160 | ||
| 2026-02-11 | Chaudhuri Sarbani See Remarks | Grant or award · Stock Option (Right to Buy) | +189,076 | 189,076 | ||
| 2026-01-02 | Bjork Elisabeth Director | Purchase | +10,000 | $3.44 | $34K | 50,000 |
| 2025-11-18 | Militello John See Remarks | Sale | −1,086 | $2.98 | $3K | 65,920 |
| 2025-11-18 | Schwartz Jonathan David See Remarks | Sale | −2,545 | $2.98 | $8K | 299,064 |
| 2025-11-18 | Shah Gaurav CEO | Sale | −6,276 | $2.98 | $19K | 778,296 |
| 2025-11-18 | Wilson Martin General Counsel | Sale | −1,646 | $2.98 | $5K | 383,816 |
| 2025-11-03 | Wilson Martin General Counsel | Grant or award | +100,000 | 385,462 | ||
| 2025-10-14 | Militello John See Remarks | Sale | −19,841 | $3.96 | $79K | 76,083 |
| 2025-10-14 | Militello John See Remarks | Sale | −5,514 | $3.97 | $22K | 70,569 |
| 2025-10-14 | Militello John See Remarks | Sale | −3,005 | $3.97 | $12K | 67,564 |
| 2025-10-14 | Militello John See Remarks | Sale | −558 | $3.98 | $2K | 67,006 |
| 2025-10-06 | Rizvi Syed Ali-aamir Chief Medical Officer | Grant or award | +283,018 | 283,018 |
Page 4 of 9 · 164 trades